Global Pulmonary Drugs Market, by Drug Class (Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, and Others), by Application (Asthma & COPD, Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 41.32 Billion in 2022 and is expected to exhibit a CAGR of 8.1% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
The major manufacturers of pulmonary drugs are focused towards development of new and innovative products with extensive Research and Development (R&D) on pulmonary drugs. For instance, in 2017, Sanofi SA completed the phase II clinical trials in April 2017 of new drug Dupilumab in association with Regeneron Pharmaceuticals. The drug is indicated for the treatment of uncontrolled asthma in children and is expected to complete its clinical trial studies in January, 2021.
Global Pulmonary Drugs Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
However, the COVID-19 pandemic had a positive impact on the global pulmonary drugs market, owing to patients with asthma and Chronic Obstructive Pulmonary Disease (COPD) considered at increased risk of death from Covid-19. For instance, in August 2021, according to data published by National Center for Biotechnology Information, approximately 25 million people in the U.S. had asthma. This equals about 1 in 13 people. About 20 million U.S. adults age 18 and older had asthma. Total number of people with asthma death is 10,342,170 all over the world in 2020.
Global Pulmonary Drugs Market: Key Developments
On April 1 2022, Penn Medicine, the University of Pennsylvania Health System, a major multi-hospital health system discovered a new type of cell that resides deep within human lungs and may play a key role in human lung diseases. The researchers, analyzed human lung tissue to identify the new cells, which they called respiratory airway secretory cells (RASCs). The cells line tiny airway branches, deep in the lungs, near the alveoli structures where oxygen is exchanged for carbon dioxide. The scientists showed that Renal Allograft Compartment Syndrome (RASCs) have stem-cell-like properties enabling them to regenerate other cells that are essential for the normal functioning of alveoli. They also found evidence that cigarette smoking and the common smoking-related ailment called chronic obstructive pulmonary disease (COPD) can disrupt the regenerative functions of Renal Allograft Compartment Syndrome (RASCs)—hinting that correcting this disruption could be a good way to treat COPD.
Browse 50 Market Data Tables and 38 Figures spread through 304 Pages and in-depth TOC on “Global Pulmonary Drugs Market”- Forecast to 2030, Global Pulmonary Drugs Market, by Drug Class (Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, and Others), by Application (Asthma & COPD, Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the pulmonary drugs market, click the link below:
https://www.coherentmarketinsights.com/market-insight/pulmonary-drugs-market-1285
Moreover, the major manufacturers of pulmonary drugs are focused towards development of new and innovative products with extensive Research and Development (R&D) on pulmonary drugs. For instance, in 2017, Circassia Pharmaceuticals, Circassia Group PLC, a company focused on treating people suffering from respiratory diseases through its NIOX range of FeNO devices which help diagnose and manage asthma, completed Phase IV clinical trials of Tudorza with a collaborative agreement between Circassia and AstraZeneca Plc. for the treatment of COPD.
Key Takeaways of the Global Pulmonary Drugs Market:
- Global pulmonary drugs market is expected to exhibit a CAGR of 8.1% during the forecast period, owing to the presence of high potential market and increasing prevalence of chronic respiratory diseases in Asia Pacific, Latin America, the Middle East, and Africa.
- Among drug class, inhaled corticosteroids segment holds a dominant position in 2022, which is attributed to the advantages offered by the drugs that include lower concentration of drug delivery into the patient’s system allowing even distribution as well as lower risk of side effects that are usually exhibited by oral steroid consumption
- Among regions, North America is estimated to account for the largest market share in the global pulmonary drugs market over the forecast period, owing to increase in acquisition among key players present in North America region. For instance, in September 2021, Merck & Co., a U.S. based company, known as MSD outside the U.S. and Canada, acquired Acceleron Pharma Inc., a publicly traded biopharmaceutical company, for $180 per share in cash for an approximate total equity value of $11.5 billion. Acceleron is focused on harnessing the power of the transforming growth factor (TGF)-beta superfamily of proteins that is known to play a central role in the regulation of cell growth, differentiation and repair. This acquisition by Merck represents the culmination of work by Acceleron researchers successfully leveraging the company’s deep scientific expertise in the biology of the TGF-beta superfamily and driven by a resolute to delivering life-changing medicines for patients.
- Major players operating in the global pulmonary drugs market include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZenca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi farmaceutici S.p.A., Zambon Company S.p.A., Alaxia SAS, and Merck Sharp & Dohme Limited
